Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures. The company operates in four geographic segments: United States, Europe, Japan, and Inter-Continental.
Key Financial Metrics
| Metric (in millions) | Q3 2001 | Q3 2000 | 9 Months 2001 | 9 Months 2000 |
|---|---|---|---|---|
| Net Sales | $670 | $652 | $1,996 | $2,026 |
| Gross Profit | $456 | $452 | $1,292 | $1,396 |
| Gross Margin % | 68.1% | 69.3% | 64.7% | 68.9% |
| Operating Income (Loss) | $102 | $132 | $(8) | $483 |
| Net Income (Loss) | $58 | $85 | $(119) | $313 |
| Diluted EPS | $0.14 | $0.21 | $(0.30) | $0.76 |
| Cash & Equivalents | $99 | $54 | $99 | $60 |
| Total Debt (Short + Long Term) | $1,207 | $834 | $1,207 | $834 |
| Working Capital | $86 | $173 | $86 | $173 |
Note: Debt figures derived from Commercial Paper, Bank Obligations, and Long-term Debt. Working Capital calculated as Current Assets minus Current Liabilities.
Material Changes vs. Prior Period
- Revenue: Q3 2001 sales increased 3% year-over-year, while the nine-month period saw a 1% decline. Foreign currency fluctuations negatively impacted sales by approximately $22 million in Q3 and $75 million for the nine months.
- Profitability: The company reported a net loss of $119 million for the nine months ended September 30, 2001, compared to a net income of $313 million in the prior year. This reversal was driven by significant non-recurring charges.
- Acquisition Costs: The nine-month results included a $277 million charge for purchased research and development (R&D) related to acquisitions (EPI, CI, Quanam, IVT, and CPC). Additionally, a $49 million provision was recorded for excess NIR(R) coronary stent inventory due to declining demand.
- Restructuring: Costs associated with the global operations plan and plant optimization initiative totaled $46 million for the nine months, compared to $26 million in the prior year.
- Debt Levels: Total debt increased significantly to fund strategic acquisitions. Borrowings under credit facilities rose from $187 million at year-end 2000 to $550 million at September 30, 2001.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Stent Market: Management anticipates a continued decline in global NIR(R) coronary stent market share due to eroding physician acceptance. The company plans to launch the EXPRESS(TM) coronary stent in the U.S. in the second half of 2002 and a paclitaxel-eluting stent in Europe in 2002 and the U.S. in 2003.
- Cost Savings: The global operations plan is expected to achieve pre-tax operating savings of approximately $100 million in 2001, $220 million in 2002, and $250 million annually thereafter.
- Future Acquisitions: The company announced an agreement to acquire RadioTherapeutics Corporation (RTC), expected to close in December 2001. An earn-out payment of $70 million related to the IVT acquisition is expected in Q4 2001.
Risks and Contingencies
- Patent Litigation:
- Cordis/Johnson & Johnson: A jury found the NIR(R) stent infringed one claim of a Cordis patent, awarding approximately $324 million in damages. Judgment has not been entered; the company plans to appeal. Potential exposure is estimated at $324 million plus interest and future damages.
- Medtronic AVE: An arbitration panel awarded the company $169 million in damages for patent infringement by Medtronic AVE. Medtronic has appealed the court's confirmation of this award.
- Medinol: Ongoing litigation with supplier Medinol regarding trade secrets and contract breaches could impact the company's right to distribute Medinol stents.
- Regulatory and Market Risks: The company faces pressure from managed care, reimbursement changes, and the volatility of the coronary stent market. International operations are exposed to economic conditions and currency fluctuations.
- Integration Risk: Failure to successfully integrate recent acquisitions could impair the realization of strategic and financial objectives.
Investor Verification Checklist
- Inventory Valuation: Verify the status of the $43 million NIR(R) stent inventory and the likelihood of further write-downs given the declining market share.
- Litigation Outcomes: Monitor the status of the $324 million Cordis verdict appeal and the $169 million Medtronic AVE award appeal, as these represent significant contingent liabilities or assets.
- Acquisition Integration: Assess the progress of integrating EPI, CI, Quanam, IVT, and CPC, and the realization of the $277 million purchased R&D value.
- Debt Servicing: Review the company's ability to service increased debt levels ($1.2 billion total) amidst a net loss for the nine-month period.
- Product Launch Timeline: Confirm the regulatory approval and launch dates for the EXPRESS(TM) and paclitaxel-eluting stents, which are critical for future revenue growth.